– LABOR DR. WISPLINGHOFF AND LABCONNECT ANNOUNCE STRATEGIC ALLIANCE: EXPANDING GLOBAL CENTRAL LABORATORY SERVICES TO ACCELERATE DRUG DEVELOPMENT
JOHNSON CITY, Tenn. and COLOGNE, Germany, May 31, 2023 /PRNewswire/ — Labor Dr. Wisplinghoff and LabConnect today announced the start of their strategic alliance to provide high-quality, customized central laboratory services in Europe to support clinical trials worldwide. world.
Labor Dr. Wisplinghoff, located in Cologne, Germany, is one of the largest independent private medical laboratories in Europe, established over 45 years ago. LabConnect is a trusted partner for functional service provider (FSP) solutions and core lab services. For more than 20 years, LabConnect has been helping clients successfully reach clinical trial milestones faster by providing unparalleled program monitoring and support. Connecting the vast testing capabilities of Wisplinghoff laboratories and LabConnect’s extensive clinical trial services will provide its customers with the full range of services required for clinical trials in Europe and beyond.
“We are very pleased to have this strategic alliance with Labor Dr. Wisplinghoff to provide our clients with access to the highest quality scientific support and innovative laboratory tests in Europe,” explained Marc van Kempen, CEO of LabConnect EMEA.
Professor Hilmar Wisplinghoff added: “By bringing together one of the largest medical laboratories in Europe and one of the world’s leading providers of central laboratory services, I am convinced that we will be able to further enhance our contribution to healthcare and ultimately instance, to patients.
Complementary to this strategic alliance, LabConnect announced the opening of a new LabConnect facility for clinical kit construction and biorepository storage in Swalmen, The Netherlands. “These significant milestones complete the build out of the EMEA LabConnect infrastructure, further strengthening our offering to customers with a full range of global central laboratory services to meet the unique needs of clinical trials, no matter the size or complexity.” commented Marc van Kempen.
From clinical laboratory kit production, sample logistics and management, biorepository storage, laboratory sample testing and integrated data management, as well as functional scientific and technical expertise, LabConnect offers a quality experience. to make it easier for pharmaceutical and biotech companies and contract research organization (CRO) clients to achieve their clinical trial goals faster.
LabConnect Co-Founder and Chief Development Officer Jeff Mayhew stated, “With our shared mission to create healthier communities and improve the lives of patients, we are excited to collaborate with Dr. Labor Wisplinghoff to accelerate the development of new medicines for patients from all over the world.
ABOUT LABCONNECT LabConnect improves lives by partnering with pharmaceutical and biotechnology companies and contract research organizations (CROs) to accelerate the development of new medicines around the world. An independent, global, one-stop-shop focused on providing central laboratory services that are personalized, timely and flexible to meet evolving study demands from traditional to increasingly complex clinical trials.
ABOUT WORK DR. WISPLINGHOFF Labor Dr. Wisplinghoff improves patient care by providing the highest quality laboratory diagnostics to hospitals, doctor’s offices, universities, health departments and other medical entities 24 hours a day, 7 days a week, 365 days of the year. Founded in 1977 by Dr. Uta Wisplinghoff, it has become one of the largest independent clinical laboratories in Western Europe. Headquartered in Cologne, Germany, the laboratory offers its comprehensive testing capabilities to national and international clients covering all areas of clinical pathology with experienced board-certified medical specialists.
Logo – https://mma.prnewswire.com/media/1819005…
View original content: https://www.prnewswire.com/news-releases/labor-dr-wisplinghoff-y-labconnect-se-unen-para-acelerar-el-desarrollo-de-medicamentos-301838921.html
